Products

Bacillus cereus Preparation (SA38) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    • Product Name: Bacillus cereus Preparation (SA38) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: sales10@sinochem-nanjing.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    VTB
    Specifications
    HS Code 518055
    Product Name Bacillus cereus Preparation (SA38) Veterinary Grade API
    Active Ingredient Bacillus cereus SA38
    Strain SA38
    Product Type Veterinary Grade Active Pharmaceutical Ingredient
    Dosage Forms Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    Target Species Veterinary animals
    Appearance Off-white to light brown powder
    Odor Slight fermentation-like odor
    Form Powder or lyophilized powder
    Potency Typically 1x10^9 to 1x10^11 CFU/g
    Assay Viable spore count
    Identification Conforms to Bacillus cereus SA38 strain-specific identification
    Purity >= 99% relative purity of declared viable culture
    Moisture Content <= 5.0%
    Ph 6.0 to 7.5 in 1% aqueous suspension
    Solubility Dispersible in water; insoluble in organic solvents
    Particle Size 80 to 200 mesh
    Bulk Density 0.4 to 0.7 g/mL
    Gram Stain Positive
    Morphology Rod-shaped
    Oxygen Requirement Facultative anaerobic
    Spore Formation Yes
    Optimum Temperature 30-37 C
    Optimum Ph 6.0 to 7.5
    Storage Conditions Store in a cool, dry place, protected from light; long-term storage at 2-8 C
    Shelf Life 24 months from date of manufacture when stored as directed
    Packaging Sealed foil bags, fiber drums, or double-lined polyethylene containers
    Sterility Sterile or non-sterile grades available depending on dosage form
    Endotoxin <= 5 EU/mg for injectable grade
    Heavy Metals <= 10 ppm
    Arsenic <= 2 ppm
    Microbial Contamination Conforms to veterinary API microbial limits
    Manufacturing Standard GMP-compliant veterinary API manufacturing
    Usage For veterinary pharmaceutical compounding and manufacturing only
    Route Of Administration Oral, injectable, or topical depending on final dosage form

    As an accredited Bacillus cereus Preparation (SA38) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Bacillus cereus Preparation (SA38) veterinary grade API packaged in sealed foil-lined drums, 25 kg net, with dual polyethylene liners.
    Container Loading (20′ FCL) 20′ FCL holds palletized, sealed drums of Bacillus cereus Preparation (SA38) Veterinary Grade API; secured, labeled, temperature-controlled for veterinary transport.
    Shipping Bacillus cereus Preparation (SA38) Veterinary Grade API is shipped in sealed, light-resistant, tamper-evident containers under temperature-controlled conditions, typically 2–8°C or as specified. Keep dry; avoid freezing, heat, moisture, and direct sunlight. Include MSDS, COA, and regulatory documentation. Handle aseptically, especially for injectable, powder, and solution forms.
    Storage Store Bacillus cereus Preparation (SA38) in airtight, light-resistant containers under cool, dry conditions, protected from moisture, heat, contamination, and direct sunlight. Dry powders, granules, and premix generally require controlled room temperature; injections/solutions should be refrigerated at 2–8°C unless labeled otherwise. Maintain sterility, use aseptic handling, and follow manufacturer’s validated storage and expiry instructions.
    Shelf Life Typically 24–36 months if stored sealed, cool, dry, protected from light; reconstituted or compounded forms may have shorter shelf life.
    Application of Bacillus cereus Preparation (SA38) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    Spore Viability Gradient Across Conditioning Barrel Residence Time

    Integration of Bacillus cereus SA38 spore preparation into pelleted broiler finisher rations requires precise accounting for thermal inactivation kinetics during steam conditioning and die friction. Conditioning steam at 70–85°C with 20–45 s residence time produces a moisture rise to 15.0–17.5% total mass before pellet die compression. Spore survival follows a biphasic decay curve: an initial shoulder phase of 8–14 s during which the spore coat maintains structural integrity, followed by log-linear inactivation. Feed mill trials on a CPM 3020-6 pellet mill with 66 mm die thickness and 4.0 mm hole diameter recorded spore recovery of 78–91% at die exit when mash temperature was held below 80°C, whereas recovery dropped to 43–58% at 88°C die temperature. Pellet hardness measured by Kahl hardness tester at 2.5–3.5 kg/cm² did not correlate with spore loss; die temperature and conditioner steam pressure were the dominant variables. Post-pellet counterflow cooling reduced internal pellet temperature from 82°C to 28°C within 6–8 min, but residual heat in the pellet core continued spore inactivation for approximately 40–60 s after cooling belt discharge. Formulators must therefore overage the API by 0.35–0.55 log10 CFU/g to compensate for total process losses when final feed label claim is set at 1 × 10⁶ CFU/g. Spore count verification per ISO 16140-3:2021 requires heat shock recovery at 80°C for 12 min followed by plating on Mannitol Egg Yolk Polymyxin B agar, with colony confirmation by lecithinase reaction and β-hemolysis absence on sheep blood agar. Moisture in the finished pellet must not exceed 12.0% because spore germination is triggered above water activity 0.60 aw; germination before oral ingestion renders the vegetative cells susceptible to gastric acid destruction and negates the formulation intent.

    What Limits Blend Uniformity at 1 × 10⁶ CFU/g Target Inclusion in Ribbon Mixers?

    The primary manufacturing constraint for SA38 spore powder in vitamin-mineral premix applications is not biological but physical: the lyophilized spore cake carries a bulk density of 0.38–0.45 g/cm³, which differs sharply from calcium carbonate diluent at 1.10–1.25 g/cm³ and wheat middlings carrier at 0.50–0.60 g/cm³. Segregation in a horizontal ribbon mixer with 1.0 m³ working capacity and 25–35 rpm shaft speed becomes measurable after 8–10 min of mixing time, as denser diluent particles settle toward the trough bottom while spore aggregates rise against the batch surface. Coefficient of variation (CV) for spore distribution at 10 min mixing typically ranges between 12–18% when direct addition of undiluted API to the full carrier charge is attempted. Stepwise geometric dilution is mandatory: API is first blended with microcrystalline cellulose at a 1:10 mass ratio for 5 min, then this pre-blend is incorporated into milled rice hulls at 1:10 again, producing a 1:100 dilution that can be reliably dispersed across the full premix batch with a final CV below 5% as measured by replicate sampling per ISO 6490-1:2022. Electrostatic charging of the spore powder presents a secondary process risk: lyophilized spore cakes develop surface charge densities sufficient to cause adhesion to stainless steel walls, reducing actual spore flux by 2–7% of the weighed API charge unless grounding cables are attached to mixer troughs and discharge gates. Relative humidity in the blending room must be maintained between 35–45% because spore agglomeration accelerates above 55% RH and electrostatic discharge becomes uncontrollable below 25% RH. A ribbon mixer equipped with a high-shear chopper running at 1,450 rpm for the final 2 min of cycle time reduces aggregate diameter to 120–200 μm, but chopper operation beyond 3 min generates localized heating of 8–12°C above jacket temperature, which can initiate premature spore germination in moist carrier matrices. Batch discharge through a 150 mm rotary valve at 12–15 rpm introduces no further segregation provided the screw conveyor downstream operates at 70–80% volumetric fill and is equipped with electrostatic grounding brushes at each coupling flange. Verification of blend uniformity requires 10 thief samples taken from the trough at points corresponding to 10%, 30%, 50%, 70%, and 90% of discharge sequence, each sample assayed in triplicate by the heat shock method described above. A CV below 6.0% is considered acceptable for final premix release per FDA 21 CFR 225.42 current good manufacturing practice for medicated feed premixes, though unmedicated microbial premixes fall under 21 CFR 225.158 only when a drug claim is asserted.

    Assembly of SA38 spore powder into gelatin capsule dosage forms for neonatal calf scours management introduces a different set of constraints centered on gastric transit timing and capsule shell disintegration. Hard gelatin capsules of size #0 or #00 containing 300–500 mg of lyophilized spore cake filled to 85–90% of shell volume with a lactose monohydrate diluent exhibit dissolution onset at 4–7 min when tested in 0.1 N hydrochloric acid at 37°C per USP <711> delayed-release apparatus specifications. However, the reticuloruminal environment of a pre-ruminant calf does not behave as a sink condition: the capsule may be retained in the esophageal groove or rumen for 10–25 min before reaching the abomasum, during which time the gelatin shell hydrates in the near-neutral ruminal fluid but does not fully dissolve. Spore release in the rumen is not intrinsically harmful, but the vegetative germination that follows exposure to pH 6.5–7.0 ruminal liquor and 39°C temperature produces cells that are then destroyed by abomasal acidification at pH 2.0–3.0 within 30 min. Enteric protection is therefore unnecessary from a survival perspective, since ungerminated spores resist acid passage, but enteric-coated capsules delay liberation until the jejunum where the spore population attaches more efficiently to intestinal mucus. The trade-off is manufacturing complexity: hydroxypropyl methylcellulose phthalate (HPMCP) enteric coatings require organic solvent spraying in a fluid-bed coater with 0.5–1.0 mm nozzle and 12–18% weight gain, and HPMCP coating solvents must be reduced below 500 ppm residual methylene chloride before lot release. Published data for the specific SA38 strain in neonatal calf enteric models is limited; most controlled studies of Bacillus cereus var. toyoi in dairy calves used feed-based delivery rather than discrete oral dosage forms. The fill weight tolerance for manual capsule filling is ±5.0%, and a benchtop capsule filler operating at 3,000 capsules/h produces consistent fill density if the spore cake is pre-sieved through a 355 μm mesh to eliminate granules larger than the capsule opening diameter.

    Reconstitution of SA38 lyophilized powder into aqueous drinking water suspensions for commercial layer flocks shifts the critical control point from drying protection to suspension homogeneity and spore sedimentation kinetics. The spore particle carries a hydrated density of 1.08–1.12 g/cm³, and in a 1,000 L header tank at 22°C, the settling velocity calculated by Stokes equation for 1.0–1.5 μm equivalent spherical diameter is approximately 0.12–0.25 mm/min. Over a 4-h medication window, this produces a sediment layer representing 30–50% of total spore mass unless continuous agitation is maintained. A submersible recirculating pump rated at 40–60 L/min and positioned 15 cm above the tank floor is sufficient to resuspend settled spores, but operator failure to activate the pump for more than 45–60 min results in irreversible loss of dose uniformity. Chlorination of the water supply at 0.5–2.0 ppm free chlorine aggressively inactivates vegetative cells but has minimal effect on mature spores over 4 h; the spore coat's impermeability to hypochlorous acid provides 1.5–2.5 log10 protection relative to vegetative bacilli. Water hardness above 300 mg/L as CaCO₃ does not interfere with spore viability but increases the ionic strength of the suspension and accelerates flocculation through double-layer compression, reducing the settling time by 15–25%. The manufacturer's recommended 0.1% sodium citrate addition to the stock solution sequesters divalent cations and maintains dispersed spore state for up to 8 h. Formulated soluble powders containing dextrose monohydrate as the primary carrier at 70–80% w/w pose a secondary fermentation risk: dissolved dextrose at 20–50 g/L in the medication tank selectively stimulates germination of the Bacillus cereus spores themselves, and the subsequent vegetative cell population doubles every 40–55 min at 25°C. The water tank must therefore be drained and rinsed after each 6 h medication session; biofilm formation on PVC pipe interiors from germinated spore populations has been documented by swab sampling in commercial layer houses after 72 h of continuous use.

    Spore Rehydration Lag Phase in Hard Water Supply Systems

    The transition from lyophilized spore cake to fully rehydrated spore in drinking water applications is not instantaneous; it follows a biphasic hydration profile measurable by differential scanning calorimetry and by germination lag-time assays. The outer spore coat absorbs water within 5–15 s at 25°C, increasing the wet diameter to 1.2–1.6 μm as the integument swells. Complete core rehydration requires transmembrane water movement into the protoplast, which is retarded by the cortex peptidoglycan's porosity and by residual dipicolinic acid-calcium chelate occupying 8–12% of core wet weight. The full hydration lag phase extends for 20–40 min at 22–25°C, but water hardness contributes a measurable retardation effect: calcium ions above 250 mg/L bind to carboxyl groups on the outer spore surface, reducing the effective permeability of the coat to incoming water molecules by 10–18%. In field conditions, a layer flock consuming medicated water with 400 mg/L hardness will receive a lower bioavailable spore dose per liter than a flock on 80 mg/L hardness water, even if the assayed spore count per ISO 16140-3:2021 is identical. The practical implication is that water hardness should be tested with a total hardness titration kit prior to selecting the API overage factor; for every 100 mg/L increment above 200 mg/L, the spore inclusion in the stock solution should be increased by 7–10% to offset the hydration lag and the subsequent reduced germination efficiency in the intestinal lumen. Water temperature below 10°C extends hydration lag to 60–90 min, and medication tanks in unheated poultry houses during winter months in temperate latitudes require tank heating to 18–22°C for reliable dose delivery. Published performance data for SA38 under controlled water hardness gradients is limited; the interaction between spore coat ion exchange and environmental divalent cation concentration has been characterized in peer-reviewed literature for Bacillus subtilis and Bacillus licheniformis spore models, and the SA38 formulation appears to follow the same physicochemical principles based on its coat protein profile. The operational boundary is explicit: do not reconstitute the API in water containing quaternary ammonium disinfectant residues above 2 ppm, as the cationic surfactant penetrates the outer spore coat and collapses the hydration gradient, resulting in a 1.0–1.8 log10 CFU/mL reduction in recoverable spores within 60 min of exposure.

    Compression of SA38 spore powder into veterinary oral tablets for companion animal gastrointestinal support confronts a mechanical stress boundary that is not obvious from the API certificate of analysis. The lyophilized spore cake is brittle under uniaxial compression; spore wall fracture initiates at compaction pressures corresponding to approximately 80–100 MPa on a rotary tablet press. A ZP-19 rotary press with 10 mm flat-faced bevel-edged punches and 6 mm die bore operating at 20–30 rpm produces main compression forces in the range of 8–14 kN, which translates to 60–110 MPa depending on tablet thickness and fill weight. Spore recovery from compressed tablets at 20 min after ejection shows a sigmoidal survival curve: forces up to 8 kN (55–65 MPa) preserve 85–95% viability, but forces above 12 kN (> 95 MPa) reduce viable spore count by 0.8–1.5 log10 CFU/tablet. Tablet hardness at 8 kN compression typically reaches only 35–50 N as measured by a Erweka TBH 225 hardness tester, which is below the 70–100 N hardness target usually required for intact blister pack rejection and handleability. Formulators face an inverse relationship between tablet mechanical strength and spore viability: direct compression with microcrystalline cellulose (Avicel PH-102) at 30–40% w/w and sodium starch glycolate at 3–5% w/w improves compressibility but requires a minimum 10 kN force to achieve a 60 N hardness threshold, which begins to encroach on the spore stress tolerance zone. Wet granulation is contraindicated: the aqueous granulation step triggers spore germination, and the subsequent drying at 35–40°C for 45–60 min reduces the spore count by 2–3 log10 CFU/g because germinated vegetative cells are destroyed by desiccation. A pre-granulated diluent approach is preferred: the diluent and disintegrant are granulated separately, dried thoroughly to 1.5–2.0% loss on drying, then blended with the spore powder as a final lubricated compression mix. Crosprovidone at 4–6% w/w serves as both disintegrant and moisture scavenger, maintaining tablet water activity below 0.45 aw during storage in high-barrier PVC-PVDC blister packs. Compressed tablets containing 1 × 10⁸ CFU per unit have demonstrated storage stability at 25°C/60% RH for 24 months in accelerated stability protocols, with spore count retention above 90% of label claim in triplicate lots. The critical incompatibility in tablet formulation is magnesium stearate: the hydrophobic film formed around spore aggregates by even 0.5% w/w magnesium stearate reduces water penetration into the tablet matrix, delaying disintegration to 25–35 min in simulated gastric fluid and reducing spore release at 30 min by 40–60%. Sodium stearyl fumarate at 1.0% w/w is the recommended alternative lubricant, as it does not form the continuous hydrophobic film observed with magnesium stearate.

    When Rotary Tablet Compression Exceeds 15 kN Punch Force

    Aquaculture feed applications for SA38 spore preparation involve a fundamentally different delivery matrix: extruded floating or sinking pellets for shrimp (Litopenaeus vannamei) and fingerling tilapia (Oreochromis niloticus) where spore survival through extrusion cooking is the primary technical hurdle. Single-screw extruders for aquafeed typically operate with barrel temperatures of 105–120°C and dough moisture of 25–30% in the preconditioner, creating a thermal environment far more severe than steam pelleting in livestock feed. Bacillus cereus spores survive brief (10–15 s) exposure at 100°C with 0.5–1.0 log10 reduction, but the combination of 115°C plus high mechanical shear in the extruder barrel generates 2.5–3.5 log10 CFU/g viability loss. Post-extrusion vacuum coating is therefore the only technically viable incorporation route for aquaculture feeds: the spore preparation is suspended in fish oil or lecithin-stabilized emulsion at 0.5–2.0% w/w of the pellet mass and sprayed onto cooled pellets (45–50°C) after the dryer discharge but before bagging. A Lödige vacuum coater with 0.8 bar negative pressure and 8–12 min residence time deposits the spore-containing oil film into pellet pores without requiring the spores to enter the extruder barrel at all. The oil film also retards spore leaching into the pond water column: without coating, free spores desorb from the pellet surface within 3–5 min of immersion, but oil-embedded spores remain associated with the pellet matrix for 20–30 min before the pellet's water stability limit is reached. Shrimp pond water at 28–32°C and 15–25 ppt salinity does not inhibit spore germination; the primary loss pathway in ponds is ingestion by the target species or by filter-feeding zooplankton before the spores can establish in the benthic biofilm. Pond water spore counts as measured by MPN technique decline by 1.5–2.5 log10 within 6 h of feeding, which correlates with shrimp foregut recovery counts and not with chemical inactivation. The operational limitation for aquaculture use is pellet water stability: spore-coated pellets must maintain structural integrity for at least 2 h after immersion to deliver the spore dose at the pond bottom where shrimp feed, and this requires pre-coating the pellet with a 2.5–3.5% alginate or starch-based binder film before the oil-spore coating is applied. Without the base binder, the oil film separates from the pellet surface and floats to the pond surface as a discrete oil slick carrying 70–85% of the spore dose away from the benthic feeding zone. Published data for SA38 in commercial shrimp pond trials is limited; extrapolated performance expectations are based on Bacillus subtilis and Bacillus pumilus spore preparations that have been more extensively characterized in aquaculture peer-reviewed literature.

    Compliance Matrix for SA38 Spore Preparation Across Typical Veterinary Feed and Dosage Form Applications
    Regulatory StandardApplication ScopeKey Provision Relevant to SA38
    FDA 21 CFR 225.42Medicated feed premix componentsBatch uniformity and assay requirements for microbial components
    FDA 21 CFR 507.20Animal food preventive controlsSupply-chain verification for microbiological hazard controls
    ISO 16140-3:2021Method verificationHeat shock recovery and colony confirmation for spore enumeration
    ISO 6490-1:2022Animal feeding stuff samplingSampling plan for batch blend uniformity assessment
    USP <711>Dissolution testingApparatus specifications for oral dosage form disintegration
    USP <51>Antimicrobial effectivenessMicrobial limit testing for non-sterile veterinary products

    Granulation of SA38 spore powder for direct incorporation into multi-species premix programs is constrained by a single dominant variable: the presence of free moisture in the granulation binder. Fluid-bed granulation of the spore API with polyvinylpyrrolidone K30 at 2–3% w/w aqueous solution produces uniform spore-diluent granules, but the binder solution itself initiates spore germination within 15–25 min of contact. The subsequent drying phase at 35–40°C fluid-bed inlet air temperature for 25–35 min then destroys the germinated vegetative cells, yielding a net spore recovery of only 30–50% of the input charge. Dry granulation by roller compaction offers a technically viable alternative: spore powder is blended with microcrystalline cellulose at 40–60% w/w and crospovidone at 3–5% w/w, then compacted at 30–45 kN/cm³ roll pressure through a Fitzpatrick IR-220 roller compactor with 1.0 mm gap width. The compacted ribbons are milled through a 0.8–1.2 mm screen, producing granules with a particle size distribution centered at 300–500 μm and a spore recovery of 85–92%. The dry granulation route preserves spore viability because the compaction stress is distributed across the granule matrix rather than applied directly to individual spore coats. Granules produced by this method exhibit excellent flow properties (Carr's index of 10–15%) and can be filled into hard gelatin capsules, compressed into tablets, or packaged as unit-dose sachets for direct oral administration in companion animals. The operational boundary for roller compaction is moisture sensitivity: the entire granulation suite must maintain 30–40% RH, and the API must arrive at the granulator with a loss on drying below 5.0%. Spore powder stored at 50–60% RH for more than 2 h before compaction shows a measurable increase in germination rate during subsequent reconstitution, indicating that the spore coat has undergone hydration-induced structural relaxation even if full germination has not occurred.

    Free Quote

    Competitive Bacillus cereus Preparation (SA38) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8618963613625

    Email: sales10@sinochem-nanjing.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Bacillus cereus Preparation (SA38) Veterinary Grade API is a spore-based bacterial active ingredient supplied as a dry powder or granular intermediate for formulation into tablets, capsules, oral powders, granules, premixes, and liquid suspensions or solutions. The SA38 designation is a manufacturer-specific strain identifier; it does not appear as a public pharmacopoeial monograph, and biological activity is declared as colony-forming units per gram (CFU/g) rather than as a weight-based chemical assay. Each batch is released against the supplier certificate of analysis, which should include spore enumeration, strain identity, moisture, water activity, and absence of toxigenic Bacillus cereus markers. The preparation is intended for veterinary use only and cannot be substituted with human probiotic material. Because Bacillus cereus sensu lato contains toxigenic variants, batch acceptance requires negative PCR results for the diarrheal enterotoxin complex genes nhe and hbl and the emetic cereulide synthetase gene ces in the specific SA38 fermentation lot.

    Which release and stability parameters govern this spore-based veterinary API?

    Release specifications for SA38 are contract-defined. In the absence of a public monograph, the following compendial methods and typical dry-powder limits are used as a compliance framework. The numerical values below are not intrinsic to all Bacillus cereus preparations; they are common acceptance ranges requested for veterinary oral APIs and must be confirmed against the approved product dossier.

    ParameterMethod / standard codeTypical limit or note
    Aerobic spore countISO 6887-1:2017 combined with ISO 4833-1:2013Not less than label claim; release overage based on VICH GL3 stability data
    MoisturePh. Eur. 2.2.32 or USP <731>Not more than 5.0% for dry powder
    Water activityISO 18787:2017Not more than 0.30
    Microbial limitsPh. Eur. 2.6.13TAMC/TYMC limits per dossier; for feed premix, absence of Salmonella in 25 g according to ISO 6579-1:2017 when required
    Enterotoxin gene markersStrain-specific PCR targeting ces, nhe, and hblNegative for emetic and diarrheagenic markers
    Endotoxin, parenteral gradePh. Eur. 2.6.14 / USP <85>Limit defined by product dossier; no universal API limit
    Particle sizeISO 13320:2020Dv50 and Dv90 contract-defined to control blend uniformity

    Stability testing is conducted under VICH GL3 for new veterinary drug substances and medicinal products. Long-term storage at 25°C/60% RH, intermediate conditions at 30°C/65% RH, and accelerated conditions at 40°C/75% RH are used to assign shelf life. Because spores are living biological units, CFU loss over time can show a shoulder phase followed by first-order loss. The release overage must be justified by the stability profile; typical overages requested for spore products range from 10% to 30%, but SA38-specific data should define the exact figure. If the product is intended for oral feed use, stability in a mineral or rice-husk carrier should be assessed separately from the neat API.

    In direct compression of spore-containing tablets, process viability is governed by blend water activity, excipient pH, and compaction pressure rather than by ambient room temperature alone. The dry spore powder is mixed in a bin blender or V-shell blender. Blend uniformity is monitored by stratified sampling and spore enumeration; a typical acceptance criterion is relative standard deviation not more than 5.0% at 10 sampling points. Excipients with water activity above 0.60 should be excluded or pre-dried, because free water can initiate germination. If magnesium stearate is used as a lubricant, total blend time should be limited to the value established in the product development report; over-lubrication can produce hydrophobic coating but does not directly destroy spores. Tablet hardness is formulation-specific. Because published data for SA38 under commercial tableting conditions are limited, each tablet formulation should include a compaction pressure-versus-spore recovery curve before scale-up. Compaction force on the rotary press is monitored with strain-gauge or piezoelectric instrumentation and recorded as compression force (kN) and dwell time.

    During capsule manufacture, spore-containing granules are filled on an intermittent-motion or continuous-motion capsule machine. The critical granulate properties are flow and bulk density. Carr index is determined by USP <1174>; values above 25% indicate poor flow and may require addition of colloidal silicon dioxide at 0.5% to 1.0% w/w. Fill weight variation is assessed on empty and filled capsules. The spore count in the finished capsule is determined by dispersing a composite of 10 capsules in phosphate buffer, heat shocking at 80°C for 10 min, and enumerating by ISO 4833-1:2013. The heat-shock step kills vegetative cells and enables selective recovery of the spore fraction. Storage of filled capsules should be in moisture-tight packaging; if the capsule shell absorbs moisture above 60% RH, gelatin or hypromellose shell softening may occur before spore loss.

    High-shear granulation thresholds and moisture-related viability loss

    Wet granulation of SA38 requires a defined granulation endpoint. High-shear mixers generate local temperature increases; a product-temperature ceiling of 40°C is often used for spore-containing veterinary granules, but strain-specific thermal stability data must justify this. Drying by fluid-bed dryer with inlet air at 55°C to 60°C and final moisture of 3.0% to 5.0% is common. If final moisture exceeds 5.0%, spore stability can decline during storage because water activity increases. Granule particle size is controlled by sieve analysis according to Ph. Eur. 2.9.12; the target fraction is selected to match the capsule dosator or tablet die fill. Batch-to-batch variability in granulated bulk density should be monitored; variations above 10% relative standard deviation can produce unacceptable fill weight variation on rotary tablet presses and dosator capsule machines.

    Process routeCritical constraintMonitoring method / typical target
    Direct compressionExcipient water activity and blend segregationISO 18787:2017; USP <905> for content uniformity
    Wet granulationProduct temperature and final moisturePh. Eur. 2.2.32; target product temperature ≤ 40°C
    Capsule fillingGranule flow and fill weight variationCarr index per USP <1174>; RSD ≤ 5.0%
    Feed pelletingHeat and steam condensationPost-pelleting spore recovery by ISO 6887-1:2017 and ISO 4833-1:2013
    Parenteral suspensionSterility and endotoxinPh. Eur. 2.6.1; Ph. Eur. 2.6.14

    Fluid-bed spray granulation provides spherical, low-dust granules suitable for sachets and feeding pumps. The inlet air temperature is maintained at 55°C to 60°C, with product temperature below 45°C, while an aqueous binder solution is sprayed at a controlled rate. Final moisture is checked by Ph. Eur. 2.2.32; if the granules leave the dryer with moisture above 5.0%, they are re-dried to maintain water activity below 0.30. The dried granules are sieved through 0.5 mm to 1.0 mm mesh, and fines below 0.1 mm are minimised because they create dust and feeding system loss. The finished granule spore count is determined after 80°C / 10 min heat shock and ISO 4833-1:2013 enumeration.

    When a spore-forming preparation is considered for parenteral administration, the formulation is a suspension rather than a true solution. The spore particles cannot be sterile-filtered after suspension formation without removing the active ingredient, and terminal moist heat sterilisation is incompatible with maintaining viable spores unless a specific heat exposure is validated. Aseptic processing is required: the vehicle is sterilised by filtration through a 0.22 µm sterilising-grade membrane, and the dry spore API is brought to the required concentration in a Grade A environment under Grade B background. Bacterial endotoxin limits for injectable veterinary products are product-specific; water for injection is controlled to 0.25 EU/mL under Ph. Eur. 2.6.14. Particle size of the suspension is measured by ISO 13320:2020; syringability and needle passage are assessed by extrusion through a 21 G to 23 G needle at defined injection speed. Published data for SA38 in parenteral dosage forms are limited; no injectable use should proceed without strain-specific safety data, including toxigenic gene absence, absence of emetic toxin production, and local tolerance studies in the target species.

    When SA38 is incorporated into heat-processed feed premixes

    Feed pelleting exposes SA38 to steam, pressure, and die friction. Conditioning at 70°C to 85°C for 30 s to 60 s is common in compound feed manufacture. The spore form generally tolerates these conditions better than vegetative Lactobacillus or Enterococcus strains; however, survival is matrix-dependent. Free moisture, organic acids, and mineral carriers can alter local water activity and pH. A post-pelleting recovery check is required. Samples of mash and pelleted feed are diluted and enumerated according to ISO 6887-1:2017 and ISO 4833-1:2013. Recovery is reported as log10 reduction from mash to pellet. Published D-values for SA38 are not available in public sources; therefore each feed mill must validate recovery on its own line, recording die size, steam pressure, conditioning temperature, and retention time.

    Oral liquids and drenches are suspensions of the spore powder in a viscous vehicle. The preparation does not dissolve. A suspending agent is required to maintain spore distribution. Compatibility studies in the final vehicle should include CFU counts at time zero, 24 h, 7 days, and end of shelf life; no single universal stabiliser can be applied. The pH of the vehicle should be maintained between 4.0 and 7.0 unless compatibility data justify otherwise, because strong acid conditions can activate spore germination or reduce viability.

    Bulk handling of the dry API requires dust control because aerosolised spores can contaminate manufacturing areas. Closed transfer systems, local exhaust ventilation, and HEPA-filtered vacuum collection are used in production suites. Storage is in sealed containers at or below 25°C with relative humidity below 60%. The material should not be exposed to open air for extended periods, because water uptake can increase water activity above 0.30 and reduce long-term spore stability. The preparation is incompatible in liquid suspension with high concentrations of aldehydes, oxidising agents, or strong organic acids unless compatibility data are available; these agents can damage the spore coat and germinant receptors.

    Unlike vegetative lactic acid bacteria, SA38 is a spore preparation, which changes storage, processing, and quality control. Vegetative cultures typically require refrigerated storage and acid-protected delivery; a dry spore API can be stored at ambient temperature when water activity is below 0.30. The spore form also enables use in pelleted feed where vegetative cells may be largely inactivated. However, spore survival does not by itself establish efficacy in the target animal; efficacy must be demonstrated in the registered veterinary product. The main difference from other spore-based veterinary preparations is the strain designation, fermentation process, and standardisation, not the class-level properties of Bacillus cereus. Because SA38 is not a public culture collection strain, identity verification and toxigenic gene absence are critical batch-release requirements. It should not be assumed that SA38 behaves identically to other B. cereus or B. subtilis spore products under identical drying and pelleting conditions.

    Top